Arbor Biotechnologies

CAMBRIDGE, MA · Founded 2016 · CIK 0001707499 · Biotech · Private

Programmable DNA editors for genetic medicine

arbor.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$227M
2 Form D · Nov 2021
59 months since last filing
Contracts
—
No federal contracts on record
Patents
40
15 granted · 25 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$12,224,999
Private capital raisedForm D · SEC$214,999,926
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2787Veradermics—$269M
2788Avalyn Pharma—$242M
2789Zylo Therapeutics Inc.—$4.9M
2790Arbor Biotechnologies—$227M
2791Metsera—$215M
2792Affinivax, Inc.—$233M
2793Forge Biologics Holdings, LLC—$160M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 15 related persons
  • MARK ANGELINODirector
  • DAVID CHENGExecutive Officer
  • KEITH CRANDELLDirector
  • RAMI HARAWIDirector
  • ANNIE HAZLEHURSTDirector
  • PAUL MEISTERDirector
  • KELLY MORGANExecutive Officer
  • JOHN MURPHYExecutive Officer
  • DAVID SCOTTExecutive Officer
  • DEVYN SMITHDirector · Executive Officer
  • PAM STETKIEWICZExecutive Officer
  • DAVID WALTDirector
  • WINSTON YANExecutive Officer
  • CHEN YUDirector
  • FENG ZHANGDirector

Patents

USPTO · 15 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.